Yes I agree on the long term CSL will do well with $1B R&D budget. But on the short term with this uncertainty on their revenue, I doubt investors will be paying high PE multiple. CSL will have to demonstrate some visible potential products which are almost ready for the market or Vifor & Vaccine business come up with compensating increase in revenue. I think that is there issue at the moment.
Yes I agree on the long term CSL will do well with $1B R&D...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$289.22 |
Change
0.120(0.04%) |
Mkt cap ! $139.6B | |||
| Open | High | Low | Value | Volume |
| $288.06 | $289.47 | $287.88 | $49.72M | 172.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 77 | $289.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $289.22 | 17 | 4 |
View Market Depth
| Last trade - 13.06pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$289.38 |
Change
0.120 ( 0.10 %) |
||||
| Open | High | Low | Volume | ||
| $288.40 | $289.45 | $287.66 | 22339 | ||
| Last updated 13.24pm 17/06/2024 ? | |||||
| CSL (ASX) Chart |
